UNSPSC 51413004: Itramin tosilate or itramin tosylate

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9H0R50KY0. European Medicines Agency schedules Itramin tosilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08354MIG. Itramin tosylate generally arises in the molecular formula C7H8O3S.C2H6N2O3.

The term ITRAMIN TOSYLATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) Itramin tosilate or itramin tosylate bears US NLM identifiers UMLS ID C0064114 and NCI Concept Code C83850. SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.C(CO[N+](=O)[O-])N.

UNSPSC 51413004 Itramin tosilate or itramin tosylate is a Commodity code representing a narrow pharmaceutical active ingredient with minimal visibility in recent state and local procurement activity. The code shows no direct recent solicitations for this specific compound; the three opportunities tagged to it actually solicit broader pharmaceutical products and services — advanced life support medications, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals — that are not aligned with the code's specific chemical compound name. State and local procurement in the broader pharmaceutical space involves supplying finished medications and managing pharmacy benefit programs, but this particular code does not appear to be in active use for those buys.

Tampa Fire Rescue's April 2026 sealed-bid solicitation (City of Tampa Purchasing Department, IFB 26P00188, response due April 8, 2026) is the only opportunity in the recent block that names specific medications and dosages; it targets four line items including epinephrine, labetalol, adenosine, and diltiazem for advanced life support use, with an estimated contract value of $40,000 and a one-year term plus two optional one-year renewals. The Texas Health and Human Services Commission's RFI (HHS0017013, response deadline April 3, 2026) and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals (S1070000015802, response due March 26, 2026) address pharmaceutical supply and management at a program level, not individual active ingredients. The code itself appears to sit outside current state and local procurement workflows; itramin tosilate does not appear in any recent public opportunities.